Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B
  • Sun, J-M.
  • Doi, T.
  • Enzinger, P. C.
  • Shah, M. A.
  • Adenis, A.
  • 외 5명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B
저자
Sun, J-M.Doi, T.Enzinger, P. C.Shah, M. A.Adenis, A.Wu, J.Sharan, K. P.Bhagia, P.Kato, K.Shen, L.
DOI
10.1016/j.annonc.2024.10.283
발행일
2024-12
유형
Meeting Abstract
저널명
Annals of Oncology
35
페이지
S1503 ~ S1503